Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after MenACWY-TT or Meningitec booster in children
2012-005816-25Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Meningococcal polysaccharide vaccine group W-135 and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Persistence of antibodies with respect to components of the investigational vaccine 2, 3, 4, 5, and 6 years after booster vaccination. Started May 2013; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-005816-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005816-25.